APA (7th ed.) Citation

Dreisig, K., Brünner, E. D., Marquart, H. V., Helt, L. R., Nersting, J., Frandsen, T. L., . . . Schmiegelow, K. (2021). TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia. Pediatric Hematology & Oncology, 38(3), 227. https://doi.org/10.1080/08880018.2020.1842570

Chicago Style (17th ed.) Citation

Dreisig, Karin, et al. "TPMT Polymorphisms and Minimal Residual Disease After 6-mercaptopurine Post-remission Consolidation Therapy of Childhood Acute Lymphoblastic Leukaemia." Pediatric Hematology & Oncology 38, no. 3 (2021): 227. https://doi.org/10.1080/08880018.2020.1842570.

MLA (9th ed.) Citation

Dreisig, Karin, et al. "TPMT Polymorphisms and Minimal Residual Disease After 6-mercaptopurine Post-remission Consolidation Therapy of Childhood Acute Lymphoblastic Leukaemia." Pediatric Hematology & Oncology, vol. 38, no. 3, 2021, p. 227, https://doi.org/10.1080/08880018.2020.1842570.